Eurofins Has Entered a Liquidity Contract With Kepler Cheuvreux
27 Octobre 2021 - 05:50PM
Business Wire
Regulatory News:
Eurofins Scientific S.E.
(“Eurofins” or the “Company”) (Paris:ERF) announces it has signed
an agreement with Kepler Cheuvreux to implement a liquidity
contract in order to enhance the liquidity of Eurofins’ shares on
Euronext Paris (ISIN: FR0014000MR3) (the “Agreement”).
The Agreement commences on 1
November 2021, ends on 31 December 2021 and is renewable for
one-year periods thereafter. EUR 15 million have been allocated by
Eurofins to a liquidity account for the implementation of the
Agreement.
This Agreement is in
accordance with the provisions of Regulation (EU) No. 596/2014 of
the European Parliament and of the Council of April 16, 2014 on
market abuse (MAR); the Commission Delegated Regulation (EU)
2016/908 of 26 February 2016 supplementing Regulation (EU) No.
596/2014 of the European Parliament and of the Council with
regulatory technical standards on the criteria, procedure and
requirements for the establishment of an admitted market practice
and the requirements for maintaining, discontinuing or modifying
its conditions of admission; Article 430-15 of Luxembourg law of 10
August 1915, as amended; Applicable regulations of the French
Financial Markets Association (AMF), specifically articles 221-3
and 524-4; and AMF decision n° 2021-01 of 22 June 2021, applicable
as of 1 July 2021.
This Agreement will be
suspended under the conditions referred to in Article 5 of the
decision n° AMF 2021-01 of 22 June 2021, or at the request of
Eurofins Scientific S.E. for a defined period.
The Agreement may be
terminated at any time by Eurofins without notice, or by Kepler
Cheuvreux with one month's notice. It will also automatically
terminate if Eurofins’ shares are transferred to another stock
market.
Notes to Editors:
For more information, please visit www.eurofins.com
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. Eurofins is the global leader in
food, environment, pharmaceutical and cosmetic product testing and
in agroscience Contract Research services. Eurofins is also one of
the market leaders in certain testing and laboratory services for
genomics, discovery pharmacology, forensics, BioPharma Contract
Development and Manufacturing, advanced material sciences and in
the support of clinical studies. The Group also has a rapidly
developing presence in highly specialised and molecular clinical
diagnostic testing and in-vitro diagnostic products.
With 55,000 staff across a decentralised and entrepreneurial
network of 900 laboratories in over 50 countries, Eurofins offers a
portfolio of over 200,000 analytical methods to evaluate the
safety, identity, composition, authenticity, origin, traceability
and purity of a wide range of products, as well as providing
innovative clinical diagnostic testing services and in-vitro
diagnostic products.
The Group’s objective is to provide its customers with
high-quality services, innovative solutions and accurate results on
time. Eurofins is ideally positioned to support its clients’
increasingly stringent quality and safety standards and the
increasing demands of regulatory authorities as well as the
requirements of healthcare practitioners around the world.
In 2020, Eurofins reacted quickly to meet the global challenge
of COVID-19, by creating the capacity to help over 20 million
patients monthly who may have been impacted by the pandemic with
our testing products and our services and directly supporting
healthcare professionals working on the front line to fight the
virus. The Group has established widespread PCR testing
capabilities and has carried out over 30 million tests in its own
laboratories, is supporting the development of a number of vaccines
and has established its SAFER@WORK™ testing, monitoring and
consulting programmes to help ensure safer environments, travel and
events during COVID-19.
Eurofins has grown very strongly since its inception and its
strategy is to continue expanding its technology portfolio and its
geographic reach. Through R&D and acquisitions, the Group draws
on the latest developments in the field of biotechnology and
analytical chemistry to offer its clients unique analytical
solutions.
Shares in Eurofins Scientific are listed on the Euronext Paris
Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF
FP).
Until it has been lawfully made public widely by Eurofins
through approved distribution channels, this document contains
inside information for the purpose of Regulation (EU) 596/2014 of
the European Parliament and of the Council of 16 April 2014 on
market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific’s management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantees can be made as to their completeness
or validity.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211027005837/en/
Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620
E-mail: ir@eurofins.com
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024